These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 2768888)
1. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888 [TBL] [Abstract][Full Text] [Related]
2. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606 [TBL] [Abstract][Full Text] [Related]
3. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479 [TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases. Shinozaki T; Chigira M; Kato K Cancer; 1992 Jan; 69(1):108-12. PubMed ID: 1370133 [TBL] [Abstract][Full Text] [Related]
5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
6. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma. Gedik GK; Kiratli PO; Tascioglu B; Aras T Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090 [TBL] [Abstract][Full Text] [Related]
7. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Nicolini A; Ferrari P; Sagripanti A; Carpi A Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888 [TBL] [Abstract][Full Text] [Related]
8. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. Zissimopoulos A; Petrakis G; Stellos K; Baziotis N Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400 [TBL] [Abstract][Full Text] [Related]
9. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients. Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185 [No Abstract] [Full Text] [Related]
10. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas. Chigira M; Shinozaki T Arch Orthop Trauma Surg; 1990; 109(5):247-51. PubMed ID: 1702981 [TBL] [Abstract][Full Text] [Related]
11. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma. Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185 [TBL] [Abstract][Full Text] [Related]
12. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646 [TBL] [Abstract][Full Text] [Related]
13. The Role of TPS and TPA in the Diagnostics of Distant Metastases. Kucera R; Topolcan O; Fiala O; Kinkorova J; Treska V; Zedníková I; Slouka D; Simanek V; Safanda M; Babuska V Anticancer Res; 2016 Feb; 36(2):773-7. PubMed ID: 26851038 [TBL] [Abstract][Full Text] [Related]
14. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. van Dalen A Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693 [TBL] [Abstract][Full Text] [Related]
15. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. Steger GG; Mader R; Derfler K; Moser K; Dittrich C Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251 [TBL] [Abstract][Full Text] [Related]
16. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480 [TBL] [Abstract][Full Text] [Related]
17. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615 [TBL] [Abstract][Full Text] [Related]
19. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients. Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I J BUON; 2007; 12(4):505-11. PubMed ID: 18067209 [TBL] [Abstract][Full Text] [Related]
20. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Yildiz M; Oral B; Bozkurt M; Cobaner A Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]